Home
Diseases
ESCC
Clinical Trials

Clinical Trials Related to ESCC

Related studies linked through entity extraction aliases.

An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging

Status: NOT_YET_RECRUITING
Phase: PHASE2

Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)

Status: RECRUITING
Phase: NA

Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)

Status: NOT_YET_RECRUITING
Phase: PHASE2

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

Status: NOT_YET_RECRUITING
Phase: PHASE2

SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy

Status: NOT_YET_RECRUITING
Phase: PHASE2

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

Adebrelimab Neoadjuvant Treatment for Resectable ESCC

Status: NOT_YET_RECRUITING
Phase: NA

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

Status: RECRUITING
Phase: N/A

TAS-102 Plus Radiotherapy in Elderly ESCC

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Status: RECRUITING
Phase: PHASE1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Status: RECRUITING
Phase: PHASE1

Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma

Status: RECRUITING
Phase: N/A

Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer

Status: COMPLETED
Phase: PHASE2

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

Status: RECRUITING
Phase: PHASE2

Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

Status: RECRUITING
Phase: N/A

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Status: NOT_YET_RECRUITING
Phase: PHASE2

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

Status: RECRUITING
Phase: PHASE2

Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）

Status: ACTIVE_NOT_RECRUITING
Phase: NA